Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 1.91
CTIX's Cash-to-Debt is ranked lower than
71% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. CTIX: 1.91 )
Ranked among companies with meaningful Cash-to-Debt only.
CTIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 3.12 Max: No Debt
Current: 1.91
Piotroski F-Score: 2
Altman Z-Score: -6.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -540.00
CTIX's ROE % is ranked lower than
97% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. CTIX: -540.00 )
Ranked among companies with meaningful ROE % only.
CTIX' s ROE % Range Over the Past 10 Years
Min: -540  Med: -257.35 Max: -235
Current: -540
-540
-235
ROA % -122.75
CTIX's ROA % is ranked lower than
89% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. CTIX: -122.75 )
Ranked among companies with meaningful ROA % only.
CTIX' s ROA % Range Over the Past 10 Years
Min: -2870.38  Med: -215.36 Max: -99.77
Current: -122.75
-2870.38
-99.77
ROC (Joel Greenblatt) % -14860.86
CTIX's ROC (Joel Greenblatt) % is ranked lower than
90% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. CTIX: -14860.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CTIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -41215.38  Med: -33618.18 Max: -14860.86
Current: -14860.86
-41215.38
-14860.86
3-Year EBITDA Growth Rate 46.30
CTIX's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CTIX: 46.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CTIX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -5.7  Med: 46.75 Max: 94.9
Current: 46.3
-5.7
94.9
3-Year EPS without NRI Growth Rate 40.10
CTIX's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. CTIX: 40.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CTIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 42.15 Max: 100
Current: 40.1
0
100
GuruFocus has detected 1 Warning Sign with Cellceutix Corp $CTIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:NAS:INFI, OTCPK:IMMVF, OTCPK:HPPI, NAS:KIN, NAS:EGLT, NAS:ATHX, NAS:GNCA, NAS:ADVM, NAS:CXRX, NAS:LPTX, NAS:VVUS, NAS:CORI, NAS:ZFGN, OTCPK:MCUJF, NAS:CTIC, AMEX:PLX, NAS:PSTI, NAS:CDXC, NAS:EVGN, OTCPK:HSDT » details
Cellceutix Corp is a biopharmaceutical company. The Company is engaged in the business of developing small molecule therapies to treat diseases in the areas of cancer and inflammatory disease.

Cellceutix Corp was incorporated as Econoshare, Inc. on August 1, 2005, in the State of Nevada. On December 6, 2007, the Company acquired Cellceutix Pharma, Inc., a privately owned corporation formed under the laws of the State of Delaware on June 20, 2007. It is a clinical stage biopharmaceutical company developing therapies with oncology, dermatology and antimicrobial applications. It owns the rights to numerous drug compounds, including Kevetrin (thioureidobutyronitrile), an anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis; and Brilacidin. The Company's operations and activities are subject to extensive regulation by numerous government authorities in the United States and other countries.

Ratios

vs
industry
vs
history
PB Ratio 950.00
CTIX's PB Ratio is ranked lower than
100% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CTIX: 950.00 )
Ranked among companies with meaningful PB Ratio only.
CTIX' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1060
Current: 950
0
1060
Current Ratio 0.47
CTIX's Current Ratio is ranked lower than
93% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CTIX: 0.47 )
Ranked among companies with meaningful Current Ratio only.
CTIX' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.36 Max: 2.4
Current: 0.47
0.01
2.4
Quick Ratio 0.47
CTIX's Quick Ratio is ranked lower than
93% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. CTIX: 0.47 )
Ranked among companies with meaningful Quick Ratio only.
CTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.36 Max: 2.4
Current: 0.47
0.01
2.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.60
CTIX's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CTIX: -7.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CTIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -114.3  Med: -8.15 Max: -0.1
Current: -7.6
-114.3
-0.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -11.13
CTIX's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. CTIX: -11.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CTIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -12.38  Med: 0 Max: 0
Current: -11.13
-12.38
0

More Statistics

EPS (TTM) $ -0.11
Beta1.88
Short Percentage of Float0.00%
52-Week Range $0.90 - 1.92
Shares Outstanding (Mil)126.41
» More Articles for CTIX

Headlines

Articles On GuruFocus.com
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 

More From Other Websites
12:45 pm Cellceutix announced progression of ongoing Phase 2 clinical trial of Brilacidin to the... Feb 22 2017
Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission... Feb 22 2017
Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones Feb 16 2017
CELLCEUTIX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 16 2017
CELLCEUTIX CORP Financials Feb 15 2017
Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate... Feb 10 2017
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure Feb 09 2017
Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix Jan 27 2017
Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by... Jan 23 2017
Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags Jan 23 2017
Short-seller takes aim at Beverly biotech, sparking claims of 'fake news' Jan 18 2017
Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published “Fake News” Full... Jan 17 2017
Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of... Jan 17 2017
Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results Jan 04 2017
Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships Dec 22 2016
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of... Dec 19 2016
Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company... Dec 15 2016
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory... Dec 07 2016
Cellceutix Corp. :CTIX-US: Earnings Analysis: Q1, 2017 By the Numbers : November 29, 2016 Nov 29 2016
CELLCEUTIX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)